Approvals/TGA/GARDASIL HPV 6 L1 Protein / HPV 11 L1 Protein / HPV 16 L1 Protein / HPV 18 L1 Protein 20,40,40,20 micrograms/0.5mL sterile liquid syringe

Approved

STANDARD

GARDASIL HPV 6 L1 Protein / HPV 11 L1 Protein / HPV 16 L1 Protein / HPV 18 L1 Protein 20,40,40,20 micrograms/0.5mL sterile liquid syringe

Merck Sharp & Dohme (Australia) Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: 2e9beaf80958d99b
Company: Merck Sharp & Dohme (Australia) Pty Ltd
Type: Standard

Approval Details

Approval Id: 2e9beaf80958d99b
Product Name: GARDASIL HPV 6 L1 Protein / HPV 11 L1 Protein / HPV 16 L1 Protein / HPV 18 L1 Protein 20,40,40,20 micrograms/0.5mL sterile liquid syringe
Artg Id: 124410
Artg Name: GARDASIL quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine 20,40,40,20 micrograms/0.5mL sterile liquid syringe
Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
Company Detail Path: /organization/merck-sharp-and-dohme-australia-pty-ltd
Artg Date: 2006-06-22
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

2e9beaf80958d99b

Type

Standard

Back to TGA Approvals